Evidence map›Paper›PMID 30912093›Full record

ArticleSeminars in liver disease2019

Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis.

Naoto Fujiwara, Yujin Hoshida

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Seminars in liver disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Proteomic analysis of DEN and CClScientific reports · 2024
    Article
  2. Association ofWorld journal of gastrointestinal oncology · 2023
    Article
  3. Genetic Variation ofInternational journal of molecular sciences · 2022
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Naoto FujiwaraLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Yujin HoshidaLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
The University of Texas Southwestern Medical Center · USThe University of Tokyo · JP

Funding

Molecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6M
ERC-2014-AdG-671231 HEPCIR European UnionEuropean Research Council 671231NIDDK NIH HHS R01 DK099558R01 DK099558 U.S. NIH/NIDDKRR180016 Cancer Prevention and Research Institute of TexasW81XWH-16-1-0363 U.S. Department of Defense
6 · The paper itself

Abstract

Prediction of future hepatocellular carcinoma (HCC) risk in the sizable chronic liver disease population is an urgent unmet need to enable regular HCC screening for early detection. Germline deoxyribonucleic acid polymorphisms likely represent etiology-specific host factors that determine HCC susceptibility, including single nucleotide polymorphisms in

Indexed as

BiomarkersCarcinoma, HepatocellularGenetic ProfileGerm-Line MutationHepatitis BHumansLiver CirrhosisLiver NeoplasmsPolymorphism, Single NucleotideRisk AssessmentBiomarkers

Identifiers

PMID30912093
PMCPMC6641542
OpenAlexW2923900431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.